Reference is made to the stock exchange notice published on 22 April 2016 regarding the completion of a private placement with gross proceeds of NOK 23.6 million (the "Private Placement").

 

The share capital increase related to the Private Placement has now been registered with the Norwegian Register of Business Enterprises.

 

The share capital has been increased with NOK 11,800,000 through issuance of a corresponding amount of new shares. The new share capital is thus NOK 122,209,566 divided by 122,209,566 shares, each with a par value of NOK 1.

 

The new shares will be listed with and become tradable on Oslo Axess as soon as possible after a listing prospectus has been approved by the Norwegian Financial Supervisory Authority. The new shares will be temporarily issued on a separate ISIN and will not be tradable until the abovementioned listing prospectus has been approved.

 

For further information, please contact:

Jon Olav Ødegård, CEO Hofseth BioCare ASA

Tel +47 936 32 966

E-mail: joo@hofsethbiocare.no

 

About Hofseth BioCare:

HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's
objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.